TFA
RPRX icon

Toth Financial Advisory’s Royalty Pharma RPRX Stock Holding History

Toth Financial Advisory’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$144 – 987
2026
Q1 		$144 Hold
3
– – ﹤0.01% 887
2025
Q4 		$116 Buy
+3
New +$114 ﹤0.01% 883

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
KMC
Kirr Marbach & Co Columbus, Indiana $594M AUM 34% 1-Year Est. Return
TPM
Triasima Portfolio Management Montreal, Quebec, Canada $740M AUM 69.74% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Toth Financial Advisory's RPRX Position: Q2 2026 in Review

Toth Financial Advisory sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 3 shares — an estimated $144 sold.

Toth Financial Advisory first reported a position in RPRX in Q4 2025 and held it in 2 quarters. The position peaked at $144 in Q1 2026. 73 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Toth Financial Advisory reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Toth Financial Advisory sold 3 Royalty Pharma shares in Q2 2026, an estimated $144.
  • Toth Financial Advisory first reported a position in Royalty Pharma in Q4 2025 and held it in 2 quarters.
  • Toth Financial Advisory's Royalty Pharma position peaked at $144 in Q1 2026.
  • 73 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Toth Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.